> Details

Paillaud, Elena; Soubeyran, Pierre; Oubaya, Nadia; Brain, Etienne; Fonck, Marianne; Reinald, Nicoleta; Heitz, Damien; Allain, Mylene; Zebachi, Sonia; Rousselot, Hubert; Laurent, Marie; Dauba, Jérôme; Caillet, Philippe; Bastuji-Garin, Sylvie; Rainfray, Muriel; Bringuier, Michael; Grellety, Thomas; Bellera, Carine A.; Mathoulin-Pélissier, Simone; Canoui-Poitrine, Florence

Prognostic value of routine biomarkers in older patients with cancer: Pooled analysis of three prospective cohorts

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Prognostic value of routine biomarkers in older patients with cancer: Pooled analysis of three prospective cohorts
  • Contributor: Paillaud, Elena; Soubeyran, Pierre; Oubaya, Nadia; Brain, Etienne; Fonck, Marianne; Reinald, Nicoleta; Heitz, Damien; Allain, Mylene; Zebachi, Sonia; Rousselot, Hubert; Laurent, Marie; Dauba, Jérôme; Caillet, Philippe; Bastuji-Garin, Sylvie; Rainfray, Muriel; Bringuier, Michael; Grellety, Thomas; Bellera, Carine A.; Mathoulin-Pélissier, Simone; Canoui-Poitrine, Florence
  • Published: American Society of Clinical Oncology (ASCO), 2019
  • Published in: Journal of Clinical Oncology, 37 (2019) 15_suppl, Seite 11551-11551
  • Language: English
  • DOI: 10.1200/jco.2019.37.15_suppl.11551
  • ISSN: 0732-183X; 1527-7755
  • Keywords: Cancer Research ; Oncology
  • Origination:
  • Footnote:
  • Description: 11551 Background: To assess prognostic value of routine biomarkers in older patients with cancer. Methods: A pooled analysis of three prospective multicentre cohorts, ELCAPA, PHRC Aquitaine and ONCODAGE was conducted. Patients aged 70 years or older, with cancer were included. Biomarkers collected were plasmatic C-reactive protein, albumin and a combined score: Glasgow Prognostic Score (GPS). The GPS comprised three categories (0: CRP≤10 mg/L, albumin≥35 g/L; 1: CRP≤10 mg/L and albumin < 35 g/L, or CRP > 10 mg/L and albumin≥35 g/L; 2: CRP > 10 mg/L and albumin < 35 g/L).The primary endpoint was overall survival at 12 months. Multivariable Cox models were used, adjusting for age, sex, localisation, metastatic status, performance status, frailty screening index, the G8. Discriminative properties were assessed using Harrell C index and NRI (Net Reclassification Improvement). Results: Overall 1800 patients were analyzed (ELCAPA: N = 543, PHRC Aquitaine: N = 253, ONCODAGE: N = 1004; mean age: 78.5±5.5 years; 61.7% of men; 37% metastatic; most frequent localisations: breast (34.9%) and colon-rectum (17.7%); 70.7% of patients screened at risk of frailty with G8). Overall survival was 71.1%. GPS was independently associated with death (among normal G8: GPS 1: Hazard Ratio (HR) = 4.48; 95% Confidence Interval (95% CI) = [2.03; 9.89], GPS 2: 11.64 [4.54; 29.81], among abnormal G8: GPS 1: 2.45 [1.79; 3.34], GPS 2: 3.97 [2.93; 5.37]. The addition of GPS to the clinical model (Harell C: 0.82 [0.80; 0.83]) improved discrimination (Harell C: 0.84 [0.82; 0.85], NRI: 11% [5; 19]). Conclusions: GPS could be used in older patients with cancer to help decision-making and prognosis assessment.
  • Access State: Open Access